The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.’s patritumab deruxtecan (DXd) this week, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab DXd, shows that developing antibody-drug conjugates (ADCs) is no easy task.
Key Takeaways
- 11 not-yet-approved antibody-drug conjugates are in Phase III trials.
But many companies are trying, lured by the extraordinary success of approved products such as AstraZeneca and Daiichi Sankyo’s Enhertu...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)